SLC5A2 and type 2 diabetes mellitus: In a large cohort of type 2 diabetes mellitus (T2DM) patients, a propensity-matched analysis published by Nadkarni et al. [20] showed that the CI-AKI risk was reduced with SGLT2-i treatment (HR 0.4 [95% CI: 0.2–0.7]; p = 0.01).